Financial Analysis: Oramed Pharmaceuticals (NASDAQ:ORMP) vs. Daré Bioscience (NASDAQ:DARE)

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) and Daré Bioscience (NASDAQ:DARE – Get Rating) are both small cap medical companies, but which is the better company? We’ll compare the two companies based on earnings strength, profitability, risk, valuation, analyst recommendations, institutional ownership, and dividends.

Insider and Institutional Ownership

22.4% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 8.2% of Daré Bioscience shares are held by institutional investors. 10.9% of Oramed Pharmaceuticals shares are held by company insiders. By comparison, 5.6% of Daré Bioscience shares are held by insiders of the company. Strong institutional ownership indicates that hedge funds, endowments, and large fund managers believe a company will outperform the market over the long term.

Analyst Notes

This is a summary of the current recommendations for Oramed Pharmaceuticals and Daré Bioscience, as provided by

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Oramed Pharmaceuticals 0 0 4 0 3.00
Dare Bioscience 0 0 4 0 3.00

Oramed Pharmaceuticals currently has a consensus price target of $31.75, suggesting a potential upside of 716.20%. Daré Bioscience has a consensus price target of $7.00, suggesting upside potential of 644.68%. Given Oramed Pharmaceuticals’ possible higher upside, analysts clearly believe that Oramed Pharmaceuticals is more favorable than Daré Bioscience.


This table compares the net margins, return on equity and return on assets of Oramed Pharmaceuticals and Daré Bioscience.

Net margins Return on equity return on assets
Oramed Pharmaceuticals -908.55% -24.20% -21.70%
Dare Bioscience N / A N / A N / A

Valuation and benefits

This table compares the revenue, earnings per share (EPS) and valuation of Oramed Pharmaceuticals and Daré Bioscience.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Oramed Pharmaceuticals $2.70 million 55.16 -$22.24 million ($0.77) -5.05
Dare Bioscience N / A N / A -$38.70 million ($0.70) -1.34

Oramed Pharmaceuticals has higher revenues and profits than Daré Bioscience. Oramed Pharmaceuticals trades at a lower price-to-earnings ratio than Daré Bioscience, indicating that it is currently the more affordable of the two stocks.

Volatility and risk

Oramed Pharmaceuticals has a beta of 2.02, suggesting its stock price is 102% more volatile than the S&P 500. In comparison, Daré Bioscience has a beta of 1.47, suggesting its stock price is 47% more volatile than the S&P 500.


Oramed Pharmaceuticals beats Daré Bioscience on 6 of the 11 factors compared between the two values.

Oramed Pharmaceuticals Company Profile (Get an evaluation)

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for the delivery of polypeptides. Its proprietary lead product is ORMD-0801, an orally ingestible insulin capsule, which has completed Phase II clinical trials for the treatment of people with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed Phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Company profile Daré Bioscience (Get an evaluation)

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of women’s health products in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with 2% clindamycin phosphate to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and sildenafil cream, a formulation of sildenafil cream for topical administration to the vulva and vagina for the treatment of sexual arousal disorder in women. The Company’s Phase 1-ready products are DARE-HRT1, a bio-identical intravaginal ring combination of estradiol and progesterone for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginal formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bioidentical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its preclinical-stage products include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, injectable formulations of etonogestrel to provide contraception for periods of 6 and 12 months; and DARE-RH1, a non-hormonal contraceptive for men and women. The company is headquartered in San Diego, California.

Get news and reviews for Oramed Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Oramed Pharmaceuticals and related companies with’s FREE daily newsletter.

Sarah J. Greer